Abstract
The efficacy of low-dose systemic opioids for chronic breathlessness was questioned by the recent Cochrane review by Barnes et al. We examined the reasons for this conflicting finding and re-evaluated the efficacy of systemic opioids. Compared with previous meta-analyses, Barnes et al reported a smaller effect and lower precision, but did not account for matched data of crossover trials (11/12 included trials) and added a risk-of-bias criterion (sample size). When re-analysed to account for crossover data, opioids decreased breathlessness (standardised mean differences −0.32; −0.18 to −0.47; I2=44.8%) representing a clinically meaningful reduction of 0.8 points (0–10 numerical rating scale), consistent across meta-analyses.
Original language | English |
---|---|
Pages (from-to) | 88-90 |
Number of pages | 3 |
Journal | Thorax |
Volume | 73 |
Issue number | 1 |
Early online date | 2017 |
DOIs | |
Publication status | Published - 1 Jan 2018 |
Keywords
- Chronic breathlessness
- Opioids
- Meta-analyses
- Morphine
- COPD Pharmacology
- Perception of Asthma/Breathlessness
- Palliative Care